It appears you have not yet Signed Up with our community. To Sign Up for free, please click here....



Message Board
THIS MESSAGE BOARD IS NO LONGER ACTIVE. TO SEE OUR ACTIVE MESSAGE BOARDS, PLEASE GO HERE





Message
Posted by AVN's monomice herpes cream are coming on July 11, 2000 at 07:42:56:

Rituxin (from IDPH)
was the first FDA approved drug for cancer (in the US) utilizing monoclonal antibodies.
This could have important significance to AVN if
they developed it using "monomouse" technology. AVN who owns 100% of the patent equally with IDPH has stated that
they have a verbal agreement with IDPH to commercialize "monomice" technology. If brought to the market, "monomouse"
technology may compete
with ABGX's "xenomouse" and MEDX's "humabmouse". Both ABGX and MEDX became high flying stocks this year
based on the mouse
technology. AVN, which still sells for less than $3 per share, feels that their technology is superior to that of ABGX and
MEDX. AVN has stated that they will announce plans to commercialize "monomouse" technology within 30-60 days or
sooner. AVN has also recently been approved for the first over the counter herpes cream using n-docosanol. The product
will be marketed by SBH upon final labeling approval. In addition, AVN has the exciting IgE technology in the pipeline
which may help bring relief someday to millions of allergy sufferers. The possibility of developing IgE and monoclonal
antibodies could make a perfect combination. This puts AVN in company with Genentech (DNA) who have similiar
technology using humanized antibodies.

http://biz.yahoo.com/p/a/avn.html

http://www.avanir.com/


Follow Ups

All times are GMT -7. The time now is 05:05 PM.



Site owned and operated by HealthBoards.comô
Terms of Use © 1998-2014 HealthBoards.comô All rights reserved.
Do not copy or redistribute in any form!